PROTAGONIST THERAPEUTICS INC (PTGX) Stock Fundamental Analysis

NASDAQ:PTGX • US74366E1029

82.99 USD
+0.53 (+0.64%)
At close: Feb 18, 2026
82.51 USD
-0.48 (-0.58%)
After Hours: 2/18/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to PTGX. PTGX was compared to 521 industry peers in the Biotechnology industry. PTGX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. PTGX has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • PTGX had positive earnings in the past year.
  • PTGX had a positive operating cash flow in the past year.
  • In the past 5 years PTGX reported 4 times negative net income.
  • In the past 5 years PTGX reported 4 times negative operating cash flow.
PTGX Yearly Net Income VS EBIT VS OCF VS FCFPTGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

  • PTGX has a Return On Assets of 6.54%. This is amongst the best in the industry. PTGX outperforms 92.32% of its industry peers.
  • PTGX has a Return On Equity of 7.11%. This is amongst the best in the industry. PTGX outperforms 90.98% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 2.29%, PTGX belongs to the top of the industry, outperforming 89.83% of the companies in the same industry.
Industry RankSector Rank
ROA 6.54%
ROE 7.11%
ROIC 2.29%
ROA(3y)-12.16%
ROA(5y)-18.6%
ROE(3y)-13.93%
ROE(5y)-21.46%
ROIC(3y)N/A
ROIC(5y)N/A
PTGX Yearly ROA, ROE, ROICPTGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60 -80

1.3 Margins

  • PTGX has a better Profit Margin (21.94%) than 94.24% of its industry peers.
  • The Operating Margin of PTGX (9.09%) is better than 91.17% of its industry peers.
Industry RankSector Rank
OM 9.09%
PM (TTM) 21.94%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTGX Yearly Profit, Operating, Gross MarginsPTGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • PTGX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for PTGX has been increased compared to 1 year ago.
  • The number of shares outstanding for PTGX has been increased compared to 5 years ago.
  • PTGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PTGX Yearly Shares OutstandingPTGX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PTGX Yearly Total Debt VS Total AssetsPTGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • PTGX has an Altman-Z score of 55.45. This indicates that PTGX is financially healthy and has little risk of bankruptcy at the moment.
  • PTGX's Altman-Z score of 55.45 is amongst the best of the industry. PTGX outperforms 96.55% of its industry peers.
  • PTGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 55.45
ROIC/WACC0.26
WACC8.69%
PTGX Yearly LT Debt VS Equity VS FCFPTGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 13.05 indicates that PTGX has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 13.05, PTGX belongs to the best of the industry, outperforming 88.48% of the companies in the same industry.
  • PTGX has a Quick Ratio of 13.05. This indicates that PTGX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 13.05, PTGX belongs to the top of the industry, outperforming 88.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.05
Quick Ratio 13.05
PTGX Yearly Current Assets VS Current LiabilitesPTGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • PTGX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -76.69%.
  • PTGX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -35.39%.
  • PTGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 352.10% yearly.
EPS 1Y (TTM)-76.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.81%
Revenue 1Y (TTM)-35.39%
Revenue growth 3Y151.34%
Revenue growth 5Y352.1%
Sales Q2Q%0.79%

3.2 Future

  • Based on estimates for the next years, PTGX will show a decrease in Earnings Per Share. The EPS will decrease by -5.66% on average per year.
  • PTGX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.60% yearly.
EPS Next Y-146.69%
EPS Next 2Y-70.2%
EPS Next 3Y-32.32%
EPS Next 5Y-5.66%
Revenue Next Year-84.15%
Revenue Next 2Y-5.62%
Revenue Next 3Y-24.47%
Revenue Next 5Y7.6%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PTGX Yearly Revenue VS EstimatesPTGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
PTGX Yearly EPS VS EstimatesPTGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 133.85 indicates a quite expensive valuation of PTGX.
  • Based on the Price/Earnings ratio, PTGX is valued cheaper than 89.25% of the companies in the same industry.
  • PTGX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.27.
  • The Price/Forward Earnings ratio is 222.44, which means the current valuation is very expensive for PTGX.
  • PTGX's Price/Forward Earnings ratio is rather cheap when compared to the industry. PTGX is cheaper than 87.52% of the companies in the same industry.
  • PTGX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.16.
Industry RankSector Rank
PE 133.85
Fwd PE 222.44
PTGX Price Earnings VS Forward Price EarningsPTGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150 200

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PTGX is valued cheaper than 89.64% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of PTGX indicates a rather cheap valuation: PTGX is cheaper than 91.94% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 81.44
EV/EBITDA 201.33
PTGX Per share dataPTGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • PTGX's earnings are expected to decrease with -32.32% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-70.2%
EPS Next 3Y-32.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for PTGX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PROTAGONIST THERAPEUTICS INC

NASDAQ:PTGX (2/18/2026, 8:00:01 PM)

After market: 82.51 -0.48 (-0.58%)

82.99

+0.53 (+0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-19
Inst Owners114.02%
Inst Owner Change1.57%
Ins Owners1.01%
Ins Owner Change2.09%
Market Cap5.19B
Revenue(TTM)209.22M
Net Income(TTM)45.91M
Analysts84.21
Price Target102.55 (23.57%)
Short Float %13.4%
Short Ratio9.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.83%
Min EPS beat(2)4.88%
Max EPS beat(2)6.78%
EPS beat(4)4
Avg EPS beat(4)133.89%
Min EPS beat(4)4.88%
Max EPS beat(4)504.52%
EPS beat(8)8
Avg EPS beat(8)266.75%
EPS beat(12)10
Avg EPS beat(12)179.39%
EPS beat(16)14
Avg EPS beat(16)139.25%
Revenue beat(2)1
Avg Revenue beat(2)3.47%
Min Revenue beat(2)-20.11%
Max Revenue beat(2)27.04%
Revenue beat(4)2
Avg Revenue beat(4)57.59%
Min Revenue beat(4)-20.11%
Max Revenue beat(4)232.24%
Revenue beat(8)5
Avg Revenue beat(8)57.26%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.69%
PT rev (3m)30.33%
EPS NQ rev (1m)2.83%
EPS NQ rev (3m)21.73%
EPS NY rev (1m)-0.1%
EPS NY rev (3m)2.97%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-65.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-20.13%
Valuation
Industry RankSector Rank
PE 133.85
Fwd PE 222.44
P/S 24.8
P/FCF 81.44
P/OCF 79.25
P/B 8.04
P/tB 8.04
EV/EBITDA 201.33
EPS(TTM)0.62
EY0.75%
EPS(NY)0.37
Fwd EY0.45%
FCF(TTM)1.02
FCFY1.23%
OCF(TTM)1.05
OCFY1.26%
SpS3.35
BVpS10.32
TBVpS10.32
PEG (NY)N/A
PEG (5Y)N/A
Graham Number12
Profitability
Industry RankSector Rank
ROA 6.54%
ROE 7.11%
ROCE 2.89%
ROIC 2.29%
ROICexc 18.62%
ROICexgc 18.62%
OM 9.09%
PM (TTM) 21.94%
GM N/A
FCFM 30.45%
ROA(3y)-12.16%
ROA(5y)-18.6%
ROE(3y)-13.93%
ROE(5y)-21.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 121.94%
Cap/Sales 0.84%
Interest Coverage 250
Cash Conversion 320.17%
Profit Quality 138.78%
Current Ratio 13.05
Quick Ratio 13.05
Altman-Z 55.45
F-Score5
WACC8.69%
ROIC/WACC0.26
Cap/Depr(3y)47.62%
Cap/Depr(5y)67.63%
Cap/Sales(3y)1.45%
Cap/Sales(5y)2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.81%
EPS Next Y-146.69%
EPS Next 2Y-70.2%
EPS Next 3Y-32.32%
EPS Next 5Y-5.66%
Revenue 1Y (TTM)-35.39%
Revenue growth 3Y151.34%
Revenue growth 5Y352.1%
Sales Q2Q%0.79%
Revenue Next Year-84.15%
Revenue Next 2Y-5.62%
Revenue Next 3Y-24.47%
Revenue Next 5Y7.6%
EBIT growth 1Y-87.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-196.54%
EBIT Next 3Y-33.52%
EBIT Next 5YN/A
FCF growth 1Y153.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y155.09%
OCF growth 3YN/A
OCF growth 5YN/A

PROTAGONIST THERAPEUTICS INC / PTGX FAQ

Can you provide the ChartMill fundamental rating for PROTAGONIST THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 5 / 10 to PTGX.


What is the valuation status for PTGX stock?

ChartMill assigns a valuation rating of 4 / 10 to PROTAGONIST THERAPEUTICS INC (PTGX). This can be considered as Fairly Valued.


How profitable is PROTAGONIST THERAPEUTICS INC (PTGX) stock?

PROTAGONIST THERAPEUTICS INC (PTGX) has a profitability rating of 4 / 10.


What is the valuation of PROTAGONIST THERAPEUTICS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for PROTAGONIST THERAPEUTICS INC (PTGX) is 133.85 and the Price/Book (PB) ratio is 8.04.


What is the expected EPS growth for PROTAGONIST THERAPEUTICS INC (PTGX) stock?

The Earnings per Share (EPS) of PROTAGONIST THERAPEUTICS INC (PTGX) is expected to decline by -146.69% in the next year.